EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische Übersicht

Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis

Young Ho Lee iD, Gwan Gyu Song

Diabetes, Obesity and Metabolism · 08.11.2026

DOI: 10.1111/dom.71525 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.11.2026. Verfasst von Young Ho Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of K…. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Hyperuricemia and gout are common but underappreciated comorbidities in Type 2 diabetes (T2D), obesity and chronic kidney disease (CKD). We aimed to quantify the pooled effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists on serum uric acid (SUA), incident gout and hyperuricemia, and to determine whether these effects vary by drug class and are mediated by weight loss.

Methods

We searched PubMed/MEDLINE, Embase, CENTRAL and ClinicalTrials.gov through July 2026 for RCTs of ≥ 12 weeks' duration reporting SUA change, gout flares or hyperuricemia incidence. Random‐effects meta‐analysis, subgroup and sensitivity analyses and meta‐regression were performed. Registered with PROSPERO (CRD420261468511).

Results

Eighteen RCTs (77 942 participants) met inclusion criteria. Incretin‐based therapy significantly reduced SUA versus control (weighted mean difference [WMD] −0.44 mg/dL, 95% CI −0.52 to −0.35), reduced incident gout flares (hazard ratio [HR] 0.62, 95% CI 0.53–0.72), and reduced hyperuricemia incidence (odds ratio [OR] 0.61, 95% CI 0.53–0.70). Dual GIP/GLP‐1 RA (tirzepatide) produced greater SUA lowering than mono GLP‐1 RAs (−0.62 vs. −0.35 mg/dL, p = 0.001). Body‐weight loss was a significant moderator of SUA reduction ( β = −0.041 mg/dL per kg, p < 0.001), explaining 84.7% of between‐trial heterogeneity, with a significant weight‐independent intercept (−0.19 mg/dL, p < 0.001). The SUA reduction was robust in all sensitivity analyses, including restriction to placebo‐controlled trials. GRADE certainty was high for SUA and moderate for gout flares (owing to small‐study effects) and hyperuricemia incidence.

Conclusion

Incretin‐based therapies were associated with modest reductions in SUA and with a lower incidence of gout flares and hyperuricemia, an effect largely related to weight loss. The clinical relevance of these effects, and the mechanism of any weight‐independent component, remains uncertain and warrant confirmation in dedicated trials.

Schlagwörter

Stichwörter der Autor:innen

GLP‐1 receptor agonistgouthyperuricemiameta‐analysissemaglutideserum uric acidtirzepatide

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Young Ho Lee

Zitieren

APA

Lee, Y. H., & Song, G. G. (2026). Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71525

Vancouver

Lee YH, Song GG. Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71525

BibTeX
@article{Lee2026,
  author = {Lee, Young Ho and Song, Gwan Gyu},
  title = {Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71525}
}
Kostenlos starten →